|
| Sl. no. | Synthetic drug | Data bank
(accession number) | Acts as | Mode of action |
|
| 1 | Omeprazole | DB00338 | Proton
pump inhibitor | Proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. Omeprazole blocks the final step in acid production, thus reducing gastric acidity. |
|
| 2 | Misoprostol | DB00929 | Proton
pump inhibitor | A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion and enhances mucosal resistance to injury. It is an effective antiulcer agent and also has oxytocic properties. |
|
| 3 | Pantoprazole | DB00213 | Proton
pump inhibitor | Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by forming a covalent bond to two sites of the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. |
|
| 4 | Lansoprazole | DB00448 | Proton
pump inhibitor | Lansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but rather suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. |
|
| 5 | Esomeprazole | DB00736 | Proton
pump inhibitor | Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, esomeprazole blocks the final step in acid production, thus reducing gastric acidity. |
|
| 6 | Rabeprazole | DB01129 | Proton
pump inhibitor | Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase Rabeprazole blocks the final step of gastric acid secretion. |
|
| 7 | Sucralfate | DB00364 |
In acidic environment (pH < 4) reacts with hydrochloric acid in the stomach acting as an acid buffer | Although sucralfate's mechanism is not entirely understood, there are several factors that most likely contribute to its action. In the presence of stomach acid and binds bile salts coming from the liver via the bile thus protecting the stomach lining from injury caused by the bile acids. Sucralfate may increase prostaglandin production. |
|
| 8 | Cimetidine | DB00501 | Histamine
H2-receptor antagonists | Cimetidine binds to an H2-receptor located on the basolateral membrane of the gastric parietal cell, blocking histamine effects. This competitive inhibition results in reduced gastric acid secretion and a reduction in gastric volume and acidity. |
|
| 9 | Ranitidine | DB00863 | Histamine
H2-receptor antagonists | The H2 antagonists are competitive inhibitors of histamine at the parietal cell H2-receptor. They suppress the normal secretion of acid by parietal cells and the meal-stimulated secretion of acid. |
|
| 10 | Famotidine | DB00927 | Histamine
H2-receptor antagonists | Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin. |
|
